Pacira Biosciences (PCRX) said Monday it settled the litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories related to patents for Exparel.
The parties will file consent judgments with the US Court of Appeals for the Federal Circuit and the US District Courts for the Districts of New Jersey and Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit.
In settlement of all outstanding claims in the litigations, Pacira agreed to provide Fresenius with a license to Pacira's patents to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the US beginning on an undisclosed date in early 2030.
The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of Pacira's Orange Book-listed patents for Exparel.
Exparel is a local analgesic used to decrease sensation in a small area post surgery.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。